激活素A抑制人骨髓瘤RPMI-8226细胞增殖的机制研究

雅萱 高(吉林大学基础医学院生理学系，中国)
奕迪 单(吉林大学基础医学院生理学系，中国)
忠辉 柳(吉林大学基础医学院免疫学系，中国)
敬岩 葛(吉林大学基础医学院生理学系，中国)

摘要

激活素 A 属于 TGF-β 超家族成员，具有抑制小鼠骨髓瘤细胞增殖、促进凋亡的作用，但对人骨髓瘤细胞的作用尚不清楚。本研究利用人骨髓瘤细胞系 RPMI-8226 细胞，采用 Cell Counting Kit-8 法检测激细胞活力，流式细胞术检测凋亡以及 PCR技术检测 mRNA 表达。实验结果发现，激活素 A 能够抑制 RPMI-8226 细胞活力，诱导 RPMI-8226 细胞凋亡，并且能够促进 ActRIIA 和 Smad3 的表达，提示激活素 A 通过作用于 ActRIIA-Smad3 抑制 RPMI-8226 细胞增殖。　

关键词

激活素 A； Smad 信号通路；RPMI-8226

参考

Loomans HA and Andl CD: Intertwining of activin A and TGFβ signaling: Dual roles in cancer progression and cancer cell invasion. Cancers (Basel),2014.

Morianos I, Papadopoulou G, Semitekolou M, Xanthou G.Activin-A in the regulation of immunity in health and disease. J Autoimmun,2019.

Bloise E1, Ciarmela P1, Dela Cruz C1, Luisi S1, Petraglia F1, Reis FM1. Activin A in Mammalian Physiology. Physiol Rev,2019.

Ge J, Sun H, Li J, Shan Y, Zhao Y, Liao F, Yang Y, Cui X, Liu Z. Involvement of CHOP in activin A‑induced myeloma NS‑1 cell apoptosis. Oncol Rep,2019.

Zhang Y, Qi Y, Zhao Y, Sun H, Ge J, Liu Z. Activin A induces apoptosis of mouse myeloma cells via the mitochondrial pathway. Oncol Lett,2018.

Qi Y, Ge J, Ma C, Wu N, Cui X, Liu Z. Activin A regulates activation of mouse neutrophils by Smad3 signalling. Open Biol,2017.

Olsen OE, Wader KF, Hella H, Mylin AK, Turesson, Nesthus I, Waage A, Sundan A, Holien T. Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B. Cell Commun Signal,2015.

Jeruss JS, Sturgis CD, Rademaker AW and Woodruff TK: Downregulation of activin, activin receptors, and smads in high-grade breast cancer. Cancer Res,2003.

Garcia-Gomez A, Sanchez-Guijo F, Del Cañizo MC, San Miguel JF and Garayoa M: Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics. World J Stem Cells,2014.

Wu S, Qi Y, Niu LM, Xie DX, Cui XL and Liu ZH: Activin A as a novel biomarker for colorectal adenocarcinoma in humans. Eur Rev Med Pharmacol Sci,2015.

Zessner-Spitzenberg J, Thomas AL, Krett NL, Jung B. TGFβ and activin A in the tumor microenvironment in colorectal cancer. Gene Rep,2019.

Gold E and Risbridger G: Activins and activin antagonists in the prostate and prostate cancer. Mol Cell Endocrinol,2012.

DOI: http://dx.doi.org/10.26549/yzlcyxzz.v3i2.3802